Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten

被引:126
作者
Backman, SA
Ghazarian, D
So, K
Sanchez, O
Wagner, KU
Hennighausen, L
Suzuki, A
Tsao, MS
Chapman, WB
Stambolic, V
Mak, TW
机构
[1] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Ontario Canc Inst, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada
[3] Univ Toronto, Dept Med Biophys, Hlth Network, Toronto, ON M5G 2M9, Canada
[4] Univ Toronto, Dept Lab Med & Pathobiol, Hlth Network, Toronto, ON M5G 2M9, Canada
[5] Univ Toronto, Toronto Gen Hosp, Clin Res Program, Hlth Network, Toronto, ON M5G 2C4, Canada
[6] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA
[7] NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA
[8] Akita Univ, Dept Biochem, Sch Med, Akita 0108543, Japan
关键词
D O I
10.1073/pnas.0308217100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
PTEN is a tumor suppressor gene mutated in various advanced human neoplasias, including glioblastomas and prostate, breast, endometrial, and kidney cancers. This tumor suppressor is a lipid phosphatase that negatively regulates cell survival and proliferation mediated by phosphatidylinositol 3-kinase/protein kinase B signaling. Using the Cre-IoxP system, we selectively inactivated Pten in murine tissues in which the MMTV-LTR promoter is active, resulting in hyperproliferation and neoplastic changes in Pten-null skin and prostate. These phenotypes had early onset and were completely penetrant. Abnormalities in Pten mutant skin consisted of mild epidermal hyperplasia, whereas prostates from these mice exhibited high-grade prostatic intraepithelial neoplasia (HGPIN) that frequently progressed to focally invasive cancer. These data demonstrate that Pten is an important physiological regulator of growth in the skin and prostate. Further, the early onset of HGPIN in Pten mutant males is unique to this animal model and implicates PTEN mutations in the initiation of prostate cancer. Consistent with high PTEN mutation rates in human prostate tumors, these data indicate that PTEN is a critical tumor suppressor in this organ.
引用
收藏
页码:1725 / 1730
页数:6
相关论文
共 46 条
[1]   Molecular genetics of prostate cancer [J].
Abate-Shen, C ;
Shen, MM .
GENES & DEVELOPMENT, 2000, 14 (19) :2410-2434
[2]   Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity [J].
Ali, IU ;
Schriml, LM ;
Dean, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (22) :1922-1932
[3]   Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function [J].
Anzelon, AN ;
Wu, H ;
Rickert, RC .
NATURE IMMUNOLOGY, 2003, 4 (03) :287-294
[4]   Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease [J].
Backman, SA ;
Stambolic, V ;
Suzuki, A ;
Haight, J ;
Elia, A ;
Pretorius, J ;
Tsao, MS ;
Shannon, P ;
Bolon, B ;
Ivy, GO ;
Mak, TW .
NATURE GENETICS, 2001, 29 (04) :396-403
[5]   PTEN function in mammalian cell size regulation [J].
Backman, SA ;
Stambolic, V ;
Mak, TW .
CURRENT OPINION IN NEUROBIOLOGY, 2002, 12 (05) :516-522
[6]  
Beato M., 1991, Critical Reviews in Oncogenesis, V2, P195
[7]   Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation [J].
Bierie, B ;
Nozawa, M ;
Renou, JP ;
Shillingford, JM ;
Morgan, F ;
Oka, T ;
Taketo, MM ;
Cardiff, RD ;
Miyoshi, K ;
Wagner, KU ;
Robinson, GW ;
Hennighausen, L .
ONCOGENE, 2003, 22 (25) :3875-3887
[8]   Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice [J].
Bol, DK ;
Kiguchi, K ;
GimenezConti, I ;
Rupp, T ;
DiGiovanni, J .
ONCOGENE, 1997, 14 (14) :1725-1734
[9]   DERMATOPATHOLOGY OF COWDENS SYNDROME [J].
BROWNSTEIN, MH ;
MEHREGAN, AH ;
BIKOWSKI, B ;
LUPULESCU, A ;
PATTERSON, JC .
BRITISH JOURNAL OF DERMATOLOGY, 1979, 100 (06) :667-673
[10]   Bcl-2 accelerates multistep prostate carcinogenesis in vivo [J].
Bruckheimer, EM ;
Brisbay, S ;
Johnson, DJ ;
Gingrich, JR ;
Greenberg, N ;
McDonnell, TJ .
ONCOGENE, 2000, 19 (46) :5251-5258